Clinical TrialsThe Phase I study of OV329 aims to provide more robust data for epilepsy trials, potentially boosting investor confidence in the stock.
Drug DevelopmentOV329 shows significant advantages over Vigabatrin, such as efficacy at doses 1000 times lower, which may enhance the drug's market potential.
Financial StabilityOvid Therapeutics is in a stable financial position with enough cash to fund operations into the second half of 2026, which is reassuring for investors.